Boy, was I wrong about Dendreon, analyst says

It isn't often that a Wall Street analyst admits to a mistake. But ISI Group's Mark Schoenebaum not only says he was wrong to be so optimistic about Dendreon ($DNDN) and its struggle to sell the prostate cancer treatment Provenge, he called it "the worst call of my 13 year career." Report

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.